A Pediatric Disease Designation for Argenica’s therapeutic opens the post-clinical way for a priority review and path to market.
More positive Travelan results support progression toward Phase 3 clinical trials and a pivotal FDA registration.
Manufacturing of GMP grade ARG-007 is done, and the novel neurodegenerative therapeutic is ready for next month’s Phase 2 trials.
Emyria authorised to prescribe MDMA to treat Australian’s with PTSD.
A manufacturing milestone paves the way to begin Phase 2 clinical trials and towards pivotal Phase 3 and potential partnerships.
An Orphan Designation opens up tax credits for clinical trials, user fee exemptions, and potentially seven years of market exclusivity.
Two studies establish capacity to reduce uptake of abnormal tau and further raise the profile of ARG-007 as an exciting multimodal therapeutic.
Immuron expect sales to continue as retail pharmacies restock and short-term resident returns approach pre-pandemic levels.
Many travellers can’t find an approved preventive medication, but Immuron is conducting a phase 2 clinical study to combat traveler’s diarrhea.
Stocks of the new launch product are ready in the NGS distribution warehouses to fulfil Walmart’s initial order.